Literature DB >> 30134384

Serum biomarkers of fibrosis and extracellular matrix remodeling in patients with nonalcoholic fatty liver disease: association with liver histology.

Yusuf Yilmaz1,2, Fatih Eren3,2.   

Abstract

BACKGROUND: We sought to explore the interplay of multiple serum biomarkers of fibrosis and extracellular matrix remodeling with the results of liver histology in patients with nonalcoholic fatty liver disease (NAFLD). PATIENTS AND METHODS: Venous blood samples were collected from 80 patients with biopsy-proven NAFLD and 59 age-matched and sex-matched healthy controls. Serum levels of transforming growth factor (TGF)-β1, TGF-β2, matrix metalloproteinases (MMP)-1, MMP-2, MMP-7, MMP-9, MMP-10, tissue inhibitors of metalloproteinase (TIMP)-1, and TIMP-2 were determined by using the Luminex MagPix technology on a MAGPIX analyzer.
RESULTS: We documented significant differences in the levels of TGF-β1, TGF-β2, MMP-2, MMP-7, MMP-9, TIMP-1, and TIMP-2 between NAFLD patients and controls. However, none of these biomarkers was able to distinguish between nonalcoholic steatohepatitis and nonalcoholic fatty liver. TIMP-1 levels were significantly higher in patients with significant fibrosis (fibrosis stage ≥2; 2624±1261 pg/ml) than in those without (fibrosis stage 0-1; 2096±906 pg/ml; P=0.03). Moreover, serum levels of TIMP-1 were identified as the only independent predictor of histological fibrosis (β=0.298, t=2.7, P=0.007).
CONCLUSION: Our study provides insights into the association of multiple serum biomarkers of fibrosis and extracellular matrix remodeling with NAFLD histology. Notably, serum levels of TIMP-1 were identified as a clinically useful marker for distinguishing NAFLD patients with and without significant fibrosis.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30134384     DOI: 10.1097/MEG.0000000000001240

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  14 in total

Review 1.  From the origin of NASH to the future of metabolic fatty liver disease.

Authors:  Andreas Geier; Dina Tiniakos; Helmut Denk; Michael Trauner
Journal:  Gut       Date:  2021-02-25       Impact factor: 23.059

Review 2.  Cellular protein markers, therapeutics, and drug delivery strategies in the treatment of diabetes-associated liver fibrosis.

Authors:  Chien-Yu Lin; Pratik Adhikary; Kun Cheng
Journal:  Adv Drug Deliv Rev       Date:  2021-04-20       Impact factor: 17.873

3.  Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis.

Authors:  Henrik H Hansen; Helene M Ægidius; Denise Oró; Simon S Evers; Sara Heebøll; Peter Lykke Eriksen; Karen Louise Thomsen; Anja Bengtsson; Sanne S Veidal; Michel Feigh; Malte P Suppli; Filip K Knop; Henning Grønbæk; Diego Miranda; James L Trevaskis; Niels Vrang; Jacob Jelsing; Kristoffer T G Rigbolt
Journal:  BMC Gastroenterol       Date:  2020-07-06       Impact factor: 3.067

Review 4.  Behavior of Metalloproteinases in Adipose Tissue, Liver and Arterial Wall: An Update of Extracellular Matrix Remodeling.

Authors:  Gabriela Berg; Magalí Barchuk; Verónica Miksztowicz
Journal:  Cells       Date:  2019-02-14       Impact factor: 6.600

5.  FABP4 and MMP9 levels identified as predictive factors for poor prognosis in patients with nonalcoholic fatty liver using data mining approaches and gene expression analysis.

Authors:  Audrey Coilly; Christophe Desterke; Catherine Guettier; Didier Samuel; Franck Chiappini
Journal:  Sci Rep       Date:  2019-12-24       Impact factor: 4.379

6.  A Bioreactor Technology for Modeling Fibrosis in Human and Rodent Precision-Cut Liver Slices.

Authors:  Hannah L Paish; Lee H Reed; Helen Brown; Mark C Bryan; Olivier Govaere; Jack Leslie; Ben S Barksby; Marina Garcia Macia; Abigail Watson; Xin Xu; Marco Y W Zaki; Laura Greaves; Julia Whitehall; Jeremy French; Steven A White; Derek M Manas; Stuart M Robinson; Gabriele Spoletini; Clive Griffiths; Derek A Mann; Lee A Borthwick; Michael J Drinnan; Jelena Mann; Fiona Oakley
Journal:  Hepatology       Date:  2019-05-28       Impact factor: 17.425

7.  Serum matrix metalloproteinase 7 (MMP7) is a biomarker of fibrosis in patients with non-alcoholic fatty liver disease.

Authors:  Katharine M Irvine; Satomi Okano; Preya J Patel; Leigh U Horsfall; Suzanne Williams; Anthony Russell; Elizabeth E Powell
Journal:  Sci Rep       Date:  2021-02-03       Impact factor: 4.379

8.  Mast Cells Induce Ductular Reaction Mimicking Liver Injury in Mice Through Mast Cell-Derived Transforming Growth Factor Beta 1 Signaling.

Authors:  Konstantina Kyritsi; Lindsey Kennedy; Vik Meadows; Laura Hargrove; Jennifer Demieville; Linh Pham; Amelia Sybenga; Debjyoti Kundu; Karla Cerritos; Fanyin Meng; Gianfranco Alpini; Heather Francis
Journal:  Hepatology       Date:  2021-04-19       Impact factor: 17.298

9.  Dihydromyricetin Protects the Liver via Changes in Lipid Metabolism and Enhanced Ethanol Metabolism.

Authors:  Joshua Silva; Xin Yu; Renita Moradian; Carson Folk; Maximilian H Spatz; Phoebe Kim; Adil A Bhatti; Daryl L Davies; Jing Liang
Journal:  Alcohol Clin Exp Res       Date:  2020-04-08       Impact factor: 3.455

10.  Expression of Matrix Metalloproteinases and Their Tissue Inhibitors in Peripheral Blood Leukocytes and Plasma of Children with Nonalcoholic Fatty Liver Disease.

Authors:  Joanna B Trojanek; Jacek Michałkiewicz; Renata Grzywa-Czuba; Wojciech Jańczyk; Lidia Gackowska; Izabela Kubiszewska; Anna Helmin-Basa; Aldona Wierzbicka-Rucińska; Mieczysław Szalecki; Piotr Socha
Journal:  Mediators Inflamm       Date:  2020-09-10       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.